Reviewed listing: NASDAQ:TVTX · Analysis dated Oct 22, 2026
It has not been confirmed whether the basis of this analysis still holds today. Read it as a dated earlier assessment; it does not establish a current buying opportunity.
How does the company make money?
Travere sells medicines for rare diseases, primarily FILSPARI for certain kidney diseases. Other drug candidates are in development.
What supports the business?
FILSPARI revenue nearly doubled in the second quarter. The additional approval for a clearly defined form of FSGS expands the potential patient population.
What could improve?
Further growth in prescriptions could allow existing sales and development costs to be covered more effectively. Successful additional products would reduce dependence on FILSPARI.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
52.58 USD is close to the strong scenario in our own valuation. The mid-case model value is 28.12 USD; a cautious threshold with a margin of safety is 25.00 USD.
What is the main risk?
Despite higher sales, there is still no reliable surplus after ongoing operations and license investments. Debt, further development payments, and dilution limit the value for current shareholders.
What is the overall assessment?
Watch: FILSPARI is growing strongly and gives Travere a genuine commercial foothold. However, the stock price already requires substantially higher sustainable surpluses, while development, licenses, and compensation consume significant cash.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign in